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Abstract
Background: Inventory control practices for adult vaccines, specifically Shingrix, in ambulatory
clinics are not well known or researched. This quality improvement project takes place at a small
healthcare organization consisting of a hospital and thirteen ambulatory clinics in Northern New
England. Seven of the thirteen clinics have the Shingrix vaccine in their inventory.
Purpose: The aim of this quality improvement project was multifaceted. The first matter was the
establishment of a two-week PAR level at seven of the thirteen ambulatory clinics connected to
the organization. The second was the design and implementation of a Shingrix vaccine
management program for seven of the thirteen ambulatory clinics. This included the
redistribution of inventory to prevent loss. Lastly, to create an inventory management education
program for our clinical staff.
Methods: A rapid review of the literature was conducted using an ELCLIPS format using the
Business Source Ultimate database. An informal framework of LEAN was used for this project.
Three months of baseline inventory evidence was collected (pre-COVID-19) and clinic PAR
levels were established from an uncertain baseline inventory and use volume estimate.
Interventions: A manual inventory count was conducted at each clinic. Purchase and billing
information was compared to the manual count obtained at each site. Two-week PAR levels
were established by comparing use tallies to a three-month use rate (pre-COVID-19). These
figures were extracted from the electronic health record. An educational plan for clinic
employees was developed and personnel from each of the seven clinics participated.
Results: Seven months following the onset of the project’s implementation there were no
recorded Shingrix vaccine losses and the administration of Shingrix vaccine has increased.

ADULT VACCINE MANAGEMENT IN AMBULATORY CLINICS

3

Significant gaps in the literature regarding inventory management and ambulatory clinics were
exposed. This quality improvement project ascertained evidence demonstrating a cost savings
was obtained through improved Shingrix vaccine inventory management.
Conclusions: There are opportunities to improve Shingrix vaccine inventory management at the
organization’s seven ambulatory clinics. The processes developed for this project are easily
replicated and sustainable. Stakeholders within the organization have deemed this project
financially beneficial to the organization and to the community: therefore, it has become a
foundation for inventory management at our thirteen clinic sites.
Keywords: outpatient and ambulatory clinics, inventory, supply chain management, cost
savings, resource stewardship, PAR levels
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A Quality Improvement Initiative to Manage Shingrix Vaccine Inventory in Ambulatory Clinics
Introduction

According to the American Hospital Association, the COVID-19 pandemic has
challenged healthcare organizations with unprecedented and unforeseen financial implications
(American Hospital Association, 2020). The National Rural Health Association reports a crucial
action in response to the COVID-19 crisis any healthcare organization can take is to keep a close
eye on expenses in order to maintain essential supplies (Birk, 2020). Vaccines are essential
supplies. Vaccines such as Shingrix can protect against shingles, which is a very painful and
costly disease. The Centers for Disease Control and Prevention (CDC) estimates one out of every
three people in the United States will develop shingles because of a previous infection commonly
known as chicken pox (CDC, 2019).
Problem Description

Herpes zoster, also known as shingles, is caused by the reactivation of the varicellazoster virus (VZV), the same virus that causes varicella (chickenpox). Reactivation of VZV that
has remained dormant within dorsal root ganglia, often for decades after the patient’s initial
exposure to the virus in the form of varicella (chickenpox), results in herpes zoster (shingles).
While usually a self-limited rash with pain, it can be far more serious as acute cases often lead to
post herpetic neuralgia (PHN) and is responsible for a significant economic burden.
Shingrix, is an FDA approved vaccine for the prevention of herpes zoster (shingles) in
adults aged 50 years and older. According to the manufacturer GSK, Shingrix is 90% effective at
preventing the reactivation of herpes zoster in adults (GSK, 2020). At one time, the demand for
the vaccine exceeded the supply and the drug was placed on long-term backorder.
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In October 2019, the clinics began overcome Shingrix vaccine shortages by establishing
individual GSK accounts and enrolling in the manufacturer’s auto shipment program.
Establishing an account with the manufacturer ensured an allocation of 10 doses of Shingrix
every three-four weeks to each clinic as opposed to 10 doses every three-four week to the
organization for distribution across the seven sites. The enrollment in GSK drop shipping
program resulted in a 700% increase in inventory. The vaccine was drop shipped from the
manufacturer to each clinic at a cost of $186.41 per vial. Direct shipping to each clinic continued
through January 2020.
In late 2019 and early 2020, large volumes of Shingrix were discovered in the
refrigerators of the seven ambulatory clinics targeted for this project amounting to thousands of
dollars of inventory with some of the Shingrix vials nearing their expiration dates. Identification
of this surplus in tandem with lack of inventory management resulted in this targeted area for
process improvement.
There was neither a formal nor an informal process for vaccine inventory management at
the ambulatory clinics. The areas of quality improvement for the clinics were to establish twoweek PAR levels for the Shingrix vaccine and to create an inventory management education
program for the clinical staff at the seven ambulatory clinic sites administering the Shingrix
vaccine.
Initially, the scope of this project was to develop an inventory management program by
establishing two-week PAR levels and for all vaccines at all thirteen ambulatory clinics. As the
COVID-19 pandemic unfolded, several constraints arose. Unforeseen disruptions in healthcare
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services resulted a paradigm shift in the delivery of care and in a project realignment. The focus
changed to only Shingrix vaccine management.
Shingrix vaccine inventory management became this project’s target because it was
thought to be the most impactful vaccine in regard to inventory management issues.
Administering the Shingrix vaccine as opposed to it sitting in clinic refrigerators would benefit
the organization financially and support the communities this healthcare organization serves
(U.S. Department of Health & Human Services, 2020). Creating inventory management
standards for the Shingrix vaccine laid a solid foundation and provided a framework for the
establishment of vaccine management across all of the thirteen ambulatory clinics.
Available Knowledge
There were significant gaps in the literature to describe and or support vaccine
management in ambulatory clinics. However, at the onset of this project, the costs realized by
this healthcare organization having Shingrix vaccine sedentary in the refrigerators equated to
thousands of dollars in inventory (Appendix A). Because there was no prior tracking of
inventory, previous loss estimates are only approximate as results were self-reported to this team.
This team became aware of four doses of Shingrix expiring prior to the onset of this project.
Additional losses and costs are innumerable to those persons afflicted with the disease shingles,
some of which may last a lifetime.
Vaccines do not just prevent or minimize disease. There are both societal and
organizational economic values to vaccination. The strength and vigor of a community’s
population is tied to the growth and sustainability of a community’s healthcare system (Toumi &
Ricciardi, 2015). Herpes zoster infections vacillate in severity and duration and have the
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potential to inflict a significant financial blow to its victim (Wingate, Stubbs, Ahmed, Mayaka,
Maneno, Ettienne, Elekwachi & Clarke-Tasker, 2018). In 2015, outpatient costs for
complications such as herpetic neuralgia estimates put the incurred costs, including medical and
employment loss, at $2.4 billion dollars for American citizens (Harvey, Prosser, Rose, OrtegaSanchez & Harpaz, 2020).
Vaccines do prevent disease. In this case, the disease shingles is 90% preventable by
receiving the Shingrix vaccine two-dose series (GSK, 2020). While 30% of the American
population will be afflicted with reactivation of the varicella virus (chicken pox) resulting in a
herpes zoster (HZ) outbreak, 10% of those persons will go onto to develop post herpetic
neuralgia (PHN). A hallmark of shingles rash is moderate to severe pain. PHN is a longer lasting
pain syndrome from resulting nerve damage caused by the virus (Friesen, Chateau, Falk, AlessiSeverini & Budgen, 2017). If one were to develop a shingles infection, having had the Shingrix
vaccination will minimize the disease effects (CDC, 2019).
Rationale
An informal framework of LEAN methodology was implemented to drive this quality
improvement project. Principles of LEAN management have been successfully employed by
healthcare organizations for decades. A team from the Massachusetts Institute of Technology
International Motor Vehicle Program created the term “Lean” to explain Toyota’s business
process (Simon & Canacari, 2012). This method sets forth a process to identify problems,
analyze the root cause of issues, develop and implement solutions and evaluate outcomes. Value
is realized by eliminating waste and consequently quality, cost and timeliness of services can be
improved using this methodology.
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A key component of LEAN this team used is known as Gemba, a Japanese word meaning
where the work occurs (Simon & Canacari, 2012). In the case of this healthcare organization, the
work occurs in ambulatory clinics and that is where this team went to develop the standards for
PAR levels, inventory management and to provide education. Supply chain management and
operational inventory levels of Shingrix vaccine have been determined by implementing PAR
levels.
PAR levels help to balance inventory needs with service needs by using ratios to
determine what the inventory needs are without compromising customer service (Wilson, Hodge
& Bivens 2015). The establishment of PAR levels is a well-known means of minimizing
expenses. Par level management is used in healthcare to keep enough inventory on hand to meet
the organization and patient needs yet not exceed a predetermined amount or PAR level thus
preventing excessive inventory and expense (Walker, 2019). Seven ambulatory clinic sites have
used PAR levels to demonstrate that the establishment and management of PAR levels using a
formula of a two-week usage of Shingrix vaccine +1 resulted in a cost reduction.
Specific Aims
The aim of this quality improvement project is multi-faceted. The first being, the
establishment of two-week PAR levels at seven ambulatory clinics for Shingrix vaccine
management; to implement a successful cost reduction Shingrix vaccine program in seven
ambulatory clinics that included the redistribution of inventory; and to create an inventory
management education program with specific training for the clinical staff. Cost reduction
measures and resource stewardship are of particular importance in a COVID-19 world and has
underscored the value of this project (Birk, 2020).
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There were significant limitations with obtaining baseline data because prior to the
development of this project as Shingrix vaccine volumes were not previously tracked or
monitored.

•

Inventory sharing and redistribution has occurred because of accurate eCW inventory.
o Shingrix inventory nearing expiration, within one month of expiration will be
redistributed to another clinic for administration thus preventing expiration of
product.
o Alternatively, eCW eligible patient reports may be run enabling outreach to
patients who are due or coming due for the vaccine.

•

A two-week PAR level program to manage Shingrix inventory was developed by July 1,
2020.

•

A clinical staff eCW training program was developed and implemented by August 1,
2020.

•

Those persons who received eCW inventory training have become responsible for
training the remainder of the clinical staff and new employees.
Methods

Context
The setting is a small healthcare organization in New England consisting of a hospital
and thirteen ambulatory care clinics seven of which administer adult vaccines. At the onset of the
project, five of the seven clinics had large amounts of the Shingrix vaccine in stock. Although
there is not an exact figure, there were hundreds of doses in inventory. During this time, the
Shingrix vaccine was nationally backordered and there were shortages across America. This
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quality improvement project occurs during the pandemic, COVID-19. In order for healthcare
operations to remain successful and cost efficient, waste elimination is key in supporting the
success of the organization (Xu, et al., 2011). Rural hospitals and healthcare organizations have
been hit particularly hard by the COVID-19 pandemic (Khullar, Bond & Schpero, 2020). These
factors have only strengthened the importance of this project.
Cost Benefit Analysis
Shingrix supply chain management was evaluated across the organization. There are
three cost analysis associated with this quality improvement project. The first is the cost incurred
by the ambulatory clinics and to the organization by having an abundance of the Shingrix
vaccine sitting in refrigerators. This is inventory that has been ordered and paid for yet has not
been administered therefore the clinic is unable to bill for the vaccine or the cost of the vaccines’
administration. In 2019, the cost of Shingrix was $186.41 per vial/dose. While the cost has
decreased, it remains significant at $136.50 per vial/dose.
The second aspect of cost analysis for this project became apparent within the first week
of the projects implementation when the team discovered that eight vials of Shingrix would soon
expire. The cost of these eight doses expiring could have resulted in a loss of $1,491.28 to the
clinic but instead resulted in a profit of $ 2,912.00. The loss of these doses due to product
expiration may also have resulted in disease. There is no way to predict the outcome of that
possibility. Because this team recognized the doses were approaching the end of viability, the
Shingrix vaccine was transported to another clinic and administered to patients before their
expiration date.
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This team was also able to redistribute 80 of 100 vials being stored in one clinic to
another site for administration. In terms of cost, this equates to nearly $15,000.00 of inventory
sitting idle in a clinic refrigerator during a time when Shingrix was nationally backorder and
shortages abound. Reports were run in eCW to identify patients who were due or coming due for
Shingrix vaccination and concurrently, Shingrix was included in pre-visit planning for upcoming
scheduled office visits. These actions thereby shrunk the Shingrix inventory of the clinic with
100 original stagnate doses to an inventory of 10 doses. The two-week PAR level for this
ambulatory clinic is currently at 20 vials.
The third cost analysis is the cost of disease prevention and long-term complications to
persons in the community. The CDC estimates that one out three persons in the U.S. will
developed shingles and of those 10% to 18% will go on to develop post herpetic pain neuralgia
(PHN) (CDC, 2019).
In 2018, outpatient disease cost estimates for non-complicated disease cases ranged from
$800 to $1,500 per patient. For those developing PHN outpatient cases can range from $1,425 to
$7,300 per patient. Productivity and work loss estimate for a non-complicated diseased person
averages $2,350 with total societal burden for all severity levels ranging from $1 billion to $1.9
billion (Wingate, et al., 2018) (Appendix A).
Interventions
In order to establish PAR levels, the team determined what data would be collected. A
process for data extraction was developed and implemented. The process consisted of using eCW
reporting to perform a three-month look back at Shingrix administration per site- pre-COVID-19
and comparing that volume with purchasing orders for the same time period in conjunction with

ADULT VACCINE MANAGEMENT IN AMBULATORY CLINICS

14

using the PharmacyKeeper program to track PAR levels at each site. Again, prior to this project,
Shingrix inventory, ordering and use was not tracked. This resulted in very little baseline data to
facilitate the process. PAR level inspection templates were designed for use with the
PharmacyKeeper program (Appendix B). Templates for vaccine ordering were designed and
implemented at the seven clinics (Appendix C). Policies for Vaccine Management and Standing
Orders for Shingrix administration were written by the team and approved by the organization’s
stakeholders (Appendix D & E). Clinic staff were educated regarding form location and use,
policies were reviewed, and PAR levels were set. Vaccine ordering forms were placed on the
organization’s Intranet for quick and easy access. An educational program demonstrating eCW
inventory use was implemented (Appendix F). Review of how withdraw Shingrix from the eCW
inventory document vaccine administration in the clinical note was conducted at seven
ambulatory clinics sites (Appendix G). A standing order for Shingrix administration was also
rolled out to the seven practices for use by medical assistants and nurses (Appendix H).
Study of Interventions
The impact of the interventions was assessed in real time in conjunction with the
organization’s pharmacy purchasing department. In order to ensure PAR level adherence, the
clinicians and practice managers at the seven sites will be provided with their Shingrix PAR
levels. Whenever an ambulatory care clinic places a vaccine order to replenish their stock, the
request is forwarded to the team for review. The team assesses several factors including if the
correct ordering form was used, if the requested vaccine volume is in accordance with the
established PAR level, is the current inventory in eCW accurate and if there a stagnant supply at
one of the clinics that could be redistributed. If anything is incongruent with the recommended
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process, the team will contact the ordering clinician to discuss and educate so corrections can be
made. Then the ordering form is returned to the pharmacy purchasing department for processing.
Measures
The processes are measured through onsite team inspections using the PharmacyKeeper
program and comparing them to eCW inventory. Inventory was continually assessed via eCW to
serve as back up for onsite inventory management. A vaccine manager at each site is responsible
for conducting weekly inventory reconciliation between the actual inventory on hand and the
eCW inventory. This ensures both accuracy of PAR levels and waste avoidance. If a Shingrix
vaccine is nearing its expiration date, the team is notified. PAR levels and inventory at other
clinics is evaluated to determine which ambulatory clinic is experiencing higher vaccine
administration rates and redistribution of the Shingrix vaccine to the higher use clinic has
occurred.
Additional ongoing assessment and evaluation will include:
•

The volume of Shingrix redistribution that is occurring. This has resulted in re-evaluation
of PAR levels for three ambulatory clinic sites.

•

Adherence to project components based on inventory evaluation and email of Shingrix
order requests from the pharmacy supply department to this team.

•

Tracking of all clinical staff trained and incorporating the training into onboarding of new
clinical staff.

•

Quarterly updates on project status to Quality Department and Pharmacy Director.

•

Monthly status updates to Practice Managers.

•

Timing of implementing other vaccines into the project.
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Analysis
The analysis of this quality improvement project is quantitative. Initially and
unexpectedly, loss prevention occurred during an on-site inventory analysis. It was discovered
there were eight doses of Shingrix near their expiration date. The eight doses were redistributed
to another clinic and administered prior to their expiration. It is the hope of this project team to
prevent Shingrix from nearing its expiration date through implementation of weekly inventory
reconciliation and close evaluation of volumes. Usage reports continue to be extracted from
eCW. This continues to allow the team to act quickly to redistribute vaccine from an office with
low usage and stagnate inventory to an office with high usage and or a patient wait list for
Shingrix vaccine. The ambulatory clinics are currently experiencing unexpected staff
absenteeism because of COVID-19 and high employment turnover rates. This has resulted in
much of this project oversite occurring by the team as opposed to clinical staff on site. This
process is in current use. Since the initial redistribution of Shingrix there has been no Shingrix
vaccine loss reported or recorded.
Ethical Considerations
There were no ethical considerations as this is a quality improvement project related to
inventory control and education of clinical staff and not a patient population. There were no
potential conflicts of interests.
Results
The scope of this project changed significantly because of COVID-19. Initially the range
of this project was to include an inventory management program for all vaccines at the thirteen
ambulatory clinics. As the COVID-19 pandemic unfolded, several constraints arose. Unforeseen
disruptions in healthcare services resulted in a project realignment and the focus changed to only
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that of the Shingrix vaccine management. Shingrix vaccine inventory management became the
target because it was thought to be the most impactful vaccine in regard to inventory
management.
The first segment of this quality improvement project was to establish a relationship with
the pharmacy personnel including the Director and Buyer. This is the early development of our
team. The team met weekly for several weeks with a PharmacyKeeper project developer to assist
the team with our projects vision and needs including program user training and education. The
PharmacyKeeper program has proven to be a useful tool for inventory management and tracking.
A great deal of collaboration occurred between the project team and the staff of the ambulatory
clinics. Through eCW reporting data extraction from the seven sites began. The team determined
the inventory in eCW was not accurate at any of the seven clinics. After onsite inventory data
was collected and purchase order information was compared two-week PAR levels were
established for each of the clinics. A literature review was also conducted and revealed
significant gaps in information and research to help facilitate this projects plan formation.
Our team forged ahead to the second stage and regular meetings were planned with
designated clinical staff at each clinic site. On occasion the meetings occurred daily because that
level of collaboration was required to solidify the foundation at each clinic site. Clinics with
excessive PAR levels worked with the team to redistribute Shingrix to clinics with known higher
usage. PAR levels were re-evaluated on at least a weekly basis for all seven ambulatory clinics.
Eight doses of soon to expire Shingrix vaccine were discovered in a clinic and the inventory was
salvaged resulting in a cost savings from loss prevention as well as a profit from administration
of the vaccine.
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The last stage of the project rollout mainly consisted of re-evaluation of the project’s
implementation and plan revisions at each clinic site. The project team held regular Zoom
meetings where project information was disseminated to each of the clinics and to the
organization stakeholders. Modification of PAR levels occurred in real time as not leave a clinic
without necessary Shingrix vaccine for their patients or risk loss due to expiration of the product.
Modification of PAR levels occurred at all sites due to a surge in office visits during the summer
once COVID-19 stress began to ease.
Site inspections continue to occur regularly to ensure eCW inventory is accurate in that
the numbers align with the actual inventory on hand. Education of our processes and policies
transpired simultaneously with the clinical staff during the onsite inventory checks. Interventions
to alter PAR levels and staff education continue at each clinic.
An unanticipated outcome occurred at one of the ambulatory clinics. The clinical staff
using tools put in place by this team, took it upon themselves to run reports in eCW to identify
those patients due or coming due for either a first or second Shingrix vaccination. Patient
outreach occurred which often resulted in a curbside nurse visit being scheduled (Appendix J).
These actions generated revenue and provided added disease protection to patients in our
community. The Shingrix vaccine is billed to insurance between $266.00 to $ 364.00 depending
on insurance type and an administration fee of $43.00.
Shingrix organization bills at $266.00 – our
vaccine cost $136.50 =

$ 129. 50
Admin fee

$ 43.00______
$172.50 per injection
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Discussion
Summary
Quality improvement projects are a healthcare organization priority, and this project was
and remains a team effort. While there were multiple iterations of this project, COVID-19
created the biggest obstacle and was the sole reason the team was required to pivot from a broad
all-encompassing vaccine management project to that of a single aspect of PAR level inventory
management for the Shingrix vaccine.
The first aim, to develop two-week PAR levels of Shingrix vaccine at seven ambulatory
clinics was achieved and has been re-evaluated and revised several times at three clinics because
of alternations in patient volume. One of the alterations became necessary because a provider relocated to another clinic and two alternations in volumes occurred at two other clinics because of
an uptick in demand thought to be in part brought on by COVID-19 and a national promotion of
vaccinations in general.
The second aim, developing and implementing a cost reduction Shingrix vaccine program
at seven ambulatory clinics is thought to be successful. However, because of a previously nonexistent inventory management program and very limited baseline data, assigning a number or
dollar figure was not possible. We do know for certain that our supply chain management now
better ensures that Shingrix vaccines are not lost due to things like temperature excursions and
inventory expiration and that our volumes are in better alignment with patient need and demand.
The third aim, developing and implementing a comprehensive vaccine inventory manage
program has been implemented across the seven ambulatory clinics. Education with our clinical
staff along with both onsite and remote PAR level inventory management monitoring continues
in conjunction with the pharmacy buyer and personnel in the clinics.
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Limitations
This quality improvement project encountered several limitations the most profound an
unanticipated was that it occurred during a pandemic. Because there was a complete lack of a
standard approach to inventory management there was limited baseline data available and the
team was unable to with certainty calculate wasted doses or unpaid claims data.
At least two barriers arose concerning clinic staff of the seven clinics. One being the
volume of staff turnover (those leaving their clinical positions) and staffing shortages and two,
the attitude of some staff member’s attitude regarding a change in, “the way we’ve always done
things.” This was especially challenging to address because it was important to balance enforcing
behavioral expectations with the need to keep bodies to renew prescriptions, room patients and
administer vaccines. There was fear that if behavior was forced to be corrected- either formally
or informally, that the employee may just seek employment elsewhere. This balance was difficult
but not insurmountable. It required more effort and finesse, and our time could have been better
spent elsewhere.
COVID-19 proved to be a limitation in that it was difficult to use previous office visit
volumes to assist in PAR level predictions (see Table 1). Additionally, the outlier clinic 3
acquired a provider and the provider’s panel during this period, which skewed our estimates.
Table 1
Clinic site
1 NJ
2 TA
3 PS
4 SE
5 SC
6 DY
7 DP

Office Visit Volume March
2019- October 2019
14,270
4,756
2,738
3,648
14,641
10,727
7,132

Office Visit Volume March
2020- October 2020
11,776
4,023
4,023
2,817
13,006
9,125
5,772
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Another limitation of the project is the use of an antiquated pharmacy purchase tracking
system. This made data extraction especially difficult as it was a manual process. Purchase
orders and invoices are stored in folders on a public drive, in monthly folders per site and in
different formats. Some of the data is available in an Excel spreadsheet while other data is the
actual manufacturer invoice scanned into a folder as a PDF.
Conclusions
This quality improvement project was also a process improvement project and was
beneficial in terms of improving the quality of care for patients, but also generating revenue and
prevented inventory loss all while working to unit our practices drawing personnel out of their
silos. Shingrix management is a critical service and should not create a financial burden for
ambulatory clinics. This team has shared and brought awareness to our clinical staff gaining
understanding of the financial aspects of immunization, including ordering, storage
administering, and documenting Shingrix vaccine so that these seven clinics can continue their
mission of helping patients stay healthy while sustaining profits for the clinics.
This project is a worthwhile endeavor. Better and more efficient methods of tracking
Shingrix vaccines have led to a decrease in the time required by clinical staff to figure out how to
manage inventory on their own and has prevented vaccine waste. This is a sustainable and
replicable project with demonstrated cost savings.
The next steps of project advancement will be to use the established framework for
Shingrix management across thirteen ambulatory clinics for all inventory including vaccines for
adults and children and medications. All aspects of inventory management for these clinics will
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directly and indirectly enhance patient quality of life and help to sustain the strength and vigor of
this small community health care system.
Sharing this project and its framework across all clinics will unify practices via inventory
management education. While each clinic once ordered supplies and suffered in silence when
found with either an abundance of inventory or not enough to meet the needs of the patients, we
have now created a true fabric of collaboration. These silos have been breached through use of
eCW and through the sharing of supplies, expenses and profits. Where once each clinic had to
order a box of 10 Rotateq or Varicella, now this team and the clinics staff at each site will help
redistribute and share inventory cost and profits across several sites.
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Appendix B
PharmacyKeeper Template (partial)

Dashboard Pharmacykeeper Inspection Completed/ Inspection History/ Scheduled Inspection for PAR Levels and Inventory
XXXX Family Practice

Scheduled Inspection Details
Location: XXXX Family Practice
Status: Completed
Scheduled Inspection Date: 09/01/2020
Actual Inspection Date: 09/14/2020
Assigned To: Tracy Colburn
Performed By: Tracy Colburn

NOTES: You may return excessive vaccine to pharmacy attn. Sara. I will check with other offices to see what we can redistribute/re-locate. Thank you.

Medication/Vaccine
Shingrix

PAR
2 doses

Amount on Hand
20

Return
18 doses (see photo)
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Vaccine Order Form
ADULT VACCINE ORDER FORM

Adult Vaccines

Alt. Names

Package Size

Hep A

Havrix

Hep B

Energix B

10 per package

Hep A & B

Twinrix

10 per package

HPV

Gardasil 9

10 per package

Meningococcal (A, C, W & Y)

MCV 4

5 per package

Meningococcal Grp B

Bexsero

Individual /10 per pack

MMR

MMRII

10 per package

Quantity

10 per package

Adult Vaccine Order Form

Influenza

Individual doses

Pneumococcal 13

Prevnar 13 (Conjugate)

Individual/10 per pack

Pneumococcal 23

Pneumovax 23
(Polysaccharide)

10 per package

Rabies

Rabavert

Individual doses

Shingles

Shringrix

10 per package

Tdap

Boostrix

Individual/10 per pack

Td

Tetanus & Diphtheria

10 per package

Tuberculin

PPD

Vial

OTHER

Appendix E
RECV'D BY Signature:

Date:

Policies
Pharmacy Signature:

Date:
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Appendix D
Policy: Vaccine Inventory Management and Reconciliation
PURPOSE:
This process is intended to promote and ensure that private and state vaccine and medication
inventory management for both adult and children's supply is consistent, occurs on a regular
basis, and that collaboration occurs amongst clinics.
POLICY:
It is essential to any medication and vaccine program that the inventory on hand is accurate and
accounted for in a timely manner. Good stewardship of vaccines and medications reduce waste
and resources of all clinics and ensures documentation in eCW and ImmPact is both accurate and
timely. Medication and vaccine inventory and reconciliation for both private and state vaccine
will occur at the end of a day or prior to the start of a day every week.
RESPONSIBILITY:
All clinical staff; Practice Managers are responsible to account for this being done on a weekly
basis; The Director of Practice Operations will designate a clinical representative to conduct
random site audits.
Definitions:
Inventory: the physical supply of medication and vaccine on hand at a point in time.
Reconciliation: the process by which one ensures all inventory is accurately accounted for and
documented utilizing par levels and inventory logs.
PROCEDURES:
1. Inventory will be manually counted and recorded once per week. This process will include
ensuring lot numbers and expiration dates are congruent with the actual inventory volume and set
par levels are being adhered to.
• If there is an abundance of inventory and or expiration dates are coming due in the next
month (or two) an attempt to re-purpose the vaccine within the organization should occur.
• Depending on the source of the medication and vaccine, options may include:
• An email to all Practice Managers notifying of the availability of soon to
expire inventory and asking if another office could use the inventory
• Sending it back to the Pharmacy (if non-VFC supply)
• Contacting ImmPact Help Desk and requesting vaccine be posted on their
website in hopes another practice outside of our organization can use the
product ( if it is a VFC/State product)

ADULT VACCINE MANAGEMENT IN AMBULATORY CLINICS
• Inventory Reports should be run from eCW and ImmPact-if applicable. If participating
with the VFC program, reports from eCW and ImmPact should be reconciled. For
medications and private vaccine (adult or child) inventory should be reconciled using
eCW inventory reports.
2. Reconciliation will occur minimally once per week when inventory is counted.
• Reconciliation may occur in different ways depending upon what the inventory
discrepancy is.
• Depending on the source of missing medication or vaccine- private or State,
options may include:
• Running reports in eCW and cross checking to ensure documentation is
done correctly
• Reviewing the daily schedule to identify flags
REFERENCES:
Vaccine Ordering and Delivery PP045 policy
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Appendix E
Policy: Vaccine Ordering and Delivery
PURPOSE:
To establish a standardized process for the ordering and delivery of vaccines from the Pharmacy
to our clinics. To provide a reference tool for all clinics regarding the availability of vaccines that
can and should be administered within the primary care setting.
POLICY STATEMENT:
It is the policy that all Primary Care Practices will have a vaccine inventory on site for adults
and children above and beyond those vaccines supplied through the State of Maine Vaccine For
Children (VFC) program. Primary Care Practices will administer most necessary and standard
vaccines and Mantoux tuberculin tests or purified protein derivative (PPD) to patients in a
timely, efficient and convenient manner.
RESPONSIBILITY:
It is the responsibility of all practice personnel and clinical support staff to provide care in
compliance with this policy.
PROCEDURE:
1. All vaccine ordering and delivery will utilize the Pharmacy Vaccine ordering form that is
available on the Approved Form section on the Intranet.
2. The ordering practice will send the completed order form via email addressed to Pharm
Req.
3. This same form will also serve as verification of receipt of the order and is to be
presented by the delivery person to receiving person to ensure accuracy of order,
accountability for accepting the order and ensuring proper refrigeration upon arrival. The
signed form is returned to the Pharmacy by the delivery person and recorded at the
pharmacy.
4. Most vaccine is available to any practice location within 24 hours of ordering.
5. Clinics are expected to manage their inventories responsibly including not having
excessive amounts of vaccines on site, rotating stock, monitoring expiration dates and
reaching out to other practices when expiration dates are nearing to decrease the
occurrence of preventable vaccine wastage.
6. Mantoux/PPD skin tests may be planted by a MA but must be read by licensed personnel
such as a RN, LPN or provider.
7. Vaccine refrigerators are to be consistently monitored to maintain temperatures between
36 to 46 degrees F or 2 to 8 degrees C, freezers are to maintain temperatures between -58
to +5 degrees F or -50 to -15 degrees C.
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REFERENCES:
Vaccines Storage and Handling Toolkit | CDC
https://www.cdc.gov/vaccines/hcp/admin/storage/toolkit/index.html
XX Policy HW.119
https://intranet.hospital.com/Quality/_layouts/15/start.aspx#/Approved%20Forms/Forms/AllItem
s.aspx
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Appendix F
Adding Vaccine into eCW Inventory

Open Vaccine Lot Number Inventory module in eCW→ Select Facility using carot → Select New
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Manually enter information in boxes and select OK.

Shingrix has been successfully added to eCW Inventory

The process is the same for all vaccines.
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Appendix G
Documentation of Administration
In the Progress Note
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Appendix H
Shingrix Standing Order
PURPOSE:
To reduce morbidity and mortality from herpes zoster infection (shingles) by vaccinating all
adults who meet the criteria established by the Centers for Disease Control and Prevention's
Advisory Committee on Immunization Practices.
POLICY:
Where allowed by state law, standing orders enable eligible nurses and other health care
professionals (e.g., pharmacists) to assess the need for vaccination and to vaccinate adults who
meet any of the criteria below.
RESPONSIBILITY:
It is the responsibility of ALL practice providers and clinical support staff to provide care in
compliance with this policy.
PROCEDURE:
1. Assess adults age 50 Years and older for need of vaccination against herpes zoster virus
infection. The CDC recommends two Intramuscular doses of Shingrix 2 to 6 months
apart. It is preferred over Zostavax and should be given to any patient 50 years of age or
older. Shingrix is appropriate for administration:
• Whether or not they report a prior episode of herpes zoster
• Whether or not they report a prior dose of Zostavax
• For those with chronic medical conditions (e.g., chronic renal failure, diabetes
mellitus, rheumatoid arthritis, chronic pulmonary disease), unless a
contraindication or precaution exists.
• Similar to Zostavax, Shingrix may be used for adults who:
• Are taking low-dose immunosuppressive therapy as this may decrease the
efficacy
• Are anticipating immunosuppression
• Have recovered from an immunocompromising illness
• Are receiving other adult vaccines in the same doctor's visit, including
those routinely recommended for adults age 50 years and older, such as
influenza and pneumococcal vaccines
• Have had a prior Zostavax > 8 weeks prior.
2. Screen for Caution & Precautions
Caution
• Do not administer to anyone with an active herpes zoster outbreak
• Do not administer to anyone who has received the live Zostavax within the last 8
weeks
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5.
6.
7.
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Precautions
• Moderate or severe acute illness with or without fever
• Live vaccine, including Zostavax in the last 8 weeks
Vaccine Information Statements (VIS)
• Provide all patients with a copy of the most current federal Vaccine Information
Statement (VIS). Provide non-English speaking patients with a copy of the VIS in
their native language.
Prepare to Administer Vaccine and refer to XX Policy:
PP009 XX Standing Orders Med Vaccine Administration for Patients One Month and
Older.
PP010 XX Standing Orders Medical Management of Vaccine Reactions in Patients one
month or Older.
HW115 Environment of Care Proper Disposal of Sharps Needles.
HW331 Infection Control Hand Hygiene Compliance.
HW119 Environment of Care Medications, Specimen and Reagent Storage
Administer Shingrix/Zoster Vaccine Recombinant Adjuvant
Document each patient's vaccine administration information and that a VIS was provided
in the electronic medical record.
Be Prepared to Manage Medical Emergencies.
To prevent syncope, vaccinate patients while they are seated or lying down and consider
observing them for 15 minutes after receipt of the vaccine.

QUALITY IMPROVEMENT:
Standing Orders are reviewed at least annually by XX lead providers for evidence-based
practice.
REFERENCES:
Immunization Action Coalition, Saint Paul, Minnesota. www.immunize.org
www.vaccineinformation.org
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Appendix I
Algorithm for Shingrix Curb-Side Nurse Visits
Booking in-Vehicle Nurse Visits for Shingrix Injection
On phone call screen patient and driver for COVID-19
symptoms per our screening algorithm? Do they answer
yes to any of the questions (fever, recent exposure cough,
etc.)

Yes

Delay book nurse visit for
vaccine administration;
notify provider of
occurrence; triage if
symptomatic person is our
patient.

No
•
•
•
•

Book nurse visit for Shingrix vaccine
noting it will be curb side visit
Advise pt/family to call before visit
with any change in health status.
Advise all pts need to be driven to the
appointment by a healthy adult.
Advise pt/family to call the

designated number when they
arrive at the office parking lot.
•

•

Re-screen pt & driver for COVID-19.
If no s/s use standing order to
administer Shingrix vaccine. If rescreening is positive for s/s delay the
vaccination and notify the provider if
the symptomatic person is our
patient. Otherwise, advise the driver
to seek medical attention at a walk-in
or with their PCP.
If both screen negative, conduct
nurse visit as normal with PPE to
include protective eye wear mask and
gloves. Obtain a temperature and
signed consent. Provide a VIS and
have the patient wait on site for 15
minutes following injection.

